Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer.

Next Previous
X
Search
Trial Profile

Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NICE
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 Jul 2011 Results of an analysis investigating estrogen receptor expression published in Breast Cancer Research and Treatment.
    • 16 Dec 2007 Status changed from recruiting to completed.
    • 01 May 2007 Primary endpoint 'Complete-pathological-response-rate' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top